Evaluating Nigeria's National Sodium Reduction Program
Evaluating Implementation and Scale-Up of Nigeria's National Sodium Reduction Program
This study is testing how well Nigeria's program to reduce salt in food works to help people eat healthier and lower their risk of high blood pressure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1350 (estimated) |
| Ages | 18 Years to 69 Years |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 3 sites (Abeokuta, Ogun State and 2 other locations) |
| Trial ID | NCT04765865 on ClinicalTrials.gov |
What this trial studies
This study assesses the implementation and scale-up of Nigeria's sodium reduction program led by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC). It employs a mixed methods design, including stakeholder interviews, population surveys, and retail surveys to evaluate the program's effectiveness. The study aims to track dietary sources of sodium and monitor sodium reduction efforts tailored to local contexts. By utilizing the WHO's SHAKE package, the program seeks to promote healthier eating and reduce hypertension risk across the population.
Who should consider this trial
Good fit: Ideal candidates for this study are male and female adults aged 18 to 69 years who are permanent residents of the study area and willing to participate.
Not a fit: Patients who may not benefit include those with severe health conditions such as heart or kidney failure, stroke, or liver disease, as well as pregnant or breastfeeding women.
Why it matters
Potential benefit: If successful, this program could significantly lower sodium intake in the Nigerian population, leading to improved cardiovascular health.
How similar studies have performed: Other studies have shown success with similar sodium reduction programs, indicating potential for effective implementation in Nigeria.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female adults (aged 18 to 69 years) * Willingness to participate * Permanent residents (a person who has been in the household for at least 6 months) of the study area * Ability to provide informed consent Exclusion Criteria: * Individuals who are unable to provide informed consent * Pregnant women, and those who are breastfeeding and/or women menstruating at the time of collection * Cognitively impaired adults * Those with known history of heart or kidney failure, stroke, liver disease * Those who recently began therapy with diuretics (less than two weeks) * Any other conditions that would make 24-hour urine collection difficult * Individuals who are not yet adults (minors): i.e. infants, children, or teenagers \<18 years old * Prisoners or other detained individuals
Where this trial is running
Abeokuta, Ogun State and 2 other locations
- Federal Medical Centre — Abeokuta, Ogun State, Nigeria (Recruiting)
- University of Abuja Teaching Hospital — Gwagwalada, Nigeria (Recruiting)
- Aminu Kano Teaching Hospital — Kano, Nigeria (Recruiting)
Study contacts
- Principal investigator: Mark D Huffman, MD, MPH — Washington University School of Medicine
- Study coordinator: Guhan Iyer, MPH
- Email: guhaniyer@wustl.edu
- Phone: 3147479487
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.